Genmab — Oktober 2017
-
European number, of course, great growth, $54 million in Q1, while the rest of world sales jumping to $87 million. So a really nice sort of 60% increase in Q2 versus Q1, which is great news. Majority of sales is still coming, and it's really driven by 2 countries, Germany and France. And those 2 combined are supplying slightly more than half of the rest of world sales at this point
-
Det giver mening,
Sukkeralf -
Man kan måske have en anelse om at der er gået noget cost/benefit i det. Måske på patienters bekostning..gud forbyde det!!
-
jep - det er den kategori, der hedder uden for pædagogisk rækkevidde
-
NICE er ikke de eneste. Sverige er også afventende: http://www.janusinfo.se/Documents/Nationellt_inforande_av_nya_lakemedel/Daratumumab-(Darzalex)-170418.pdf
-
Nå, jeg slikker sårene fra i dag...der er altid håb om at det bliver bedre i morgen
-
Håbet lever altid
-
@EL same thing in my head all day
-
@EL
-
Næh J&J skal vel heller ikke straffes? De opjusterer indtjeningen og betegner vækstraten i Darzalex som stærk. De måler tilsyneladende væksten i salget af Darzalex ift diverse Q16 kvartaler og ikke kvartalsvis 17. Jeg skal ikke gøre mig til dommer over, hvad der er mest korrekt, men blot konstatere, at jeg er glad for, at J&J synes, at uptake er stærk. Mon ikke de har noget at have det i? Det tror jeg:-)
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind